DECLAN N.C. JONES, PH.D.
LEAD JOHNSON & JOHNSON INNOVATION
Declan Jones, Ph.D. joined the Neuroscience team as Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, London in June 2013. Declan previously worked for GlaxoSmithKline’s (GSK) Centre of Excellence for External Drug Discovery (CEEDD) where, as Head of Research, he was responsible for creating scientific strategies, identifying new opportunities and managing programs from preclinical to Phase II state programs across all therapeutic areas.
Prior to GSK’s CEEDD, Declan spent nearly 14 years in neuroscience drug discovery and development within GSK, finishing as Head of In Vivo Neurobiology and Disease Area Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery and a member of the Biology Leadership team. His department was responsible for supporting the identification of 12 development candidate (NME) assets and provided in vivo support for a number of marketed assets. Declan was the recipient of a Research & Development Pipeline award in 2009 for his leadership of a schizophrenia program with a successful Phase II outcome.
Declan has over 75 peer-reviewed publications and external presentations and served as core panel member for Neuroscience on the Biotechnology and Biological Sciences Research Council (BBSRC) grant committee for a three-year term. He received his Ph.D. from the University of Bradford, United Kingdom and did post-doctoral work at Emory University in Atlanta, Georgia and University of Hertfordshire, United Kingdom, before joining the pharmaceutical industry. He chairs the Mood DAS Novel Targets Evaluation Forum (NTEF), and is currently an Executive Team member for the Dementias Platform UK and the Wellcome Trust Neuroinflammation Consortium and has recently joined the SAB for the South London and Maudsely NHS Foundation Trust Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience (King’s College London).